Medical and Pharmaceutical South Korea’s Yuhan has 690% profit spike on U.S. lung cancer drug sales Lazertinib, developed in partnership with Janssen Biotech, received FDA approval in August Rowan DunneOctober 28, 2024
Medical and Pharmaceutical Bright Minds Bio soars on US$35M private placement; up 5,400% in 5 days Developing drugs for the treatment of epilepsy, depression, obesity and other conditions is the company's forte Rowan DunneOctober 18, 2024
Medical and Pharmaceutical Wave Life Sciences brings big biotech breakthrough with RNA editing therapy RNA editing involves modifying RNA to correct or alter protein production in the body Joseph MortonOctober 16, 2024
Health & Wellness Rani Therapeutics enjoys 50% bump on insider buying spree The company focuses on oral delivery of biologics, and may be benefiting from investor speculation Joseph MortonOctober 15, 2024
Health & Wellness The five front war against cancer: A mugglehead roundup The American Cancer Society says one in four men and one in five women will develop cancer at some point in their lives Joseph MortonOctober 11, 2024
Medical and Pharmaceutical Scholar Rock stock skyrockets on successful phase 3 trial results The SAPPHIRE study demonstrated statistically significant and clinically meaningful improvements Joseph MortonOctober 7, 2024
Medical and Pharmaceutical Capricor Therapeutics gains traction with impending treatment data reveal in Czechia The biotech company will be revealing 3-year safety data on its primary drug for Duchenne muscular dystrophy next week Rowan DunneOctober 4, 2024
Medical and Pharmaceutical Onconetix shares go way up on Altos Ventures investment and stock split This oncology tech company has created the proprietary "Proclarix" blood test for diagnosing prostate cancer Rowan DunneSeptember 27, 2024
Medical and Pharmaceutical Wave Life Sciences shares pop 50% on positive clinical data for common type of muscular dystrophy Duchenne muscular dystrophy is a severe, progressive genetic disorder that primarily affects boys Joseph MortonSeptember 24, 2024
Medical and Pharmaceutical Prelude Therapeutics Incorporated shares drop 30% on clinical trial news The drug in question is also presently being tested in an ongoing dose-escalation Phase 1 trial for patients with solid tumours Joseph MortonSeptember 13, 2024